Important Update About Ketamine Treatment Fees and Insurance
Information below sent by email on February 5, 2026.
We are writing to share an important update about how ketamine infusions are billed at North Idaho Ketamine & TMS.
Effective today, February 5th, 2026, we will no longer bill insurance for IV ketamine infusions. Over the past year, insurance companies have increasingly denied or taken back payments for these treatments because IV ketamine for mental health is considered off‑label and non‑covered. These clawbacks have made it financially impossible for us to continue providing ketamine under an insurance‑based model while maintaining the quality and safety standards we believe you deserve.
.
To make this transition as fair as possible for the patients currently in treatment:
-
If you have been receiving ketamine infusions with insurance billing through our clinic, we will honor your existing insurance‑based pricing through March 21, 2026.
-
Starting March 22, 2026, all IV ketamine infusions will be private‑pay only at a rate of $450 per infusion, with payment due at the time of each visit.
Because of our in‑network relationships with insurers for other services (such as TMS), and the way insurers have responded to past submissions, we are also no longer able to provide superbills or coded receipts for ketamine infusions. Instead, we will give you a detailed payment receipt for your records, but it is not intended for insurance reimbursement.
We understand that these changes may create financial strain and difficult decisions. Our goal is to be transparent and to work with you as much as we can within these limits. If you are worried about being able to continue treatment:
-
We can review your treatment plan and discuss options for adjusting frequency when clinically appropriate.
-
We can explore whether you might be a candidate for TMS, which is often covered by insurance and remains available through our practice under your benefits.
-
We can provide information about any payment options or external financing resources that may help spread out the cost.
Your safety and well‑being remain our top priorities. We are making these changes so that we can keep offering ketamine treatment in a sustainable, ethical, and legally compliant way, rather than risk sudden disruption of care in the future.
If you have questions or would like to talk through how this affects your care, please contact us at (208)215-7936 or Help@TMHCare.com. We are here to support you through this transition.
With care,
John Thurston, MD
Founder/CEO